Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Nxera Pharma
Advertisement
Nxera Pharma FY2025 Results Signal Pipeline Expansion
TOKYO, Feb. 13, 2026 — Nxera Pharma Co., Ltd. reported its consolidated financial and operational results for FY2025, outlining...
Nxera Pharma Restructures to Accelerate Profitability and R&D Innovation
Dateline – November 17 2025 | Tokyo, Japan & Cambridge/London, UK Nxera Pharma announced a major restructuring initiative aimed...
Corbus Pharmaceuticals Raises $75M to Advance Oncology and Obesity Pipeline
Norwood, Massachusetts – October 31, 2025 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), an oncology and obesity-focused biotechnology company,...
Nxera Expands Asian Manufacturing for QUVIVIQ to Boost Supply and Profitability
TOKYO, Japan – October 31, 2025 — Nxera Pharma Co., Ltd. announced that its subsidiary, Nxera Pharma Japan, has...
Advertisement
